CCSG supplement Year 2: Creating an efficient clinical trial build system via the Clinical Trials Rapid Activation Consortium (CTRAC)

CCSG 补充第 2 年：通过临床试验快速激活联盟 (CTRAC) 创建高效的临床试验构建系统

• 批准号: 10437982
• 负责人: PETER W PISTERS
• 金额: $ 49.67万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-08-28 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10437982
• 关键词: Affect; Age; Area; Award; Basic Science; Behavioral Sciences; Biology; Budgets; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Patient; Cancer Survivorship; Caring; Catchment Area; Clinic; Clinical; Clinical Research; Clinical Research Protocols; Clinical Trials; Collaborations; Communities; Comprehensive Cancer Center; Data; Detection; Development; Diagnosis; Direct Costs; Drug Approval; E-learning; Early Diagnosis; Economically Deprived Population; Education; Educational Curriculum; Employee; Enrollment; Epigenetic Process; Faculty; Foundations; Future; Generations; Grant; Hospitals; Human; Image; Immunology; Institution; Interdisciplinary Study; Internet; Intervention; Investigation; Investments; Journals; Knowledge; Laboratories; Learning; Location; Malignant Neoplasms; Mentorship; Minority; Mission; Modeling; Molecular Epidemiology; Moon; Morbidity - disease rate; NCI-Designated Cancer Center; Newly Diagnosed; Oncology; Outcome; Participant; Patient Care; Patients; Population; Population Research; Population Sciences; Prevention; Research; Research Personnel; Research Project Grants; Research Training; Resistance; Resource Sharing; Science; Services; Specimen; System; Technology; Texas; Therapeutic Studies; Time; Training; Training Programs; Training and Education; Translational Research; Translations; Universities; University of Texas M D Anderson Cancer Center; Vision; anticancer research; base; cancer genetics; cancer health disparity; cancer prevention; cancer risk; clinical practice; community engagement; design; effective intervention; evidence base; graduate student; health disparity; human subject; improved; innovation; insight; member; mortality; multidisciplinary; operation; population based; prevent; programs; prospective; rare cancer; recruit; research clinical testing; standard of care; survivorship; targeted agent; tenure track; therapy design; treatment strategy; undergraduate education; undergraduate student

PROJECT SUMMARY/ABSTRACT MD Anderson Cancer Center is a comprehensive cancer center established within the University of Texas System in 1941. In 2017, the institution welcomed Peter Pisters, MD, as its fifth full-time president and PI of the CCSG. The mission of MD Anderson is to eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public. MD Anderson is dedicated wholly to the study of cancer involving a continuum of basic, clinical and population-based investigation, with an emphasis on multidisciplinary translational research. MD Anderson employed more than 19,530 people in FY17, including 1,743 faculty members, of whom 705 (40%) are CCSG program members. More than 137,000 people sought care at MD Anderson in FY17 of whom 20,839 were newly diagnosed cancer patients. Annual citations in Web of Science have increased 23% from 3,260 in 2013, to 4,009 in 2017, including 686 (17%) articles in journals with an impact factor >10, and 244 (6%) articles in journals with an impact factor >20. The total research budget increased 26% from $671M in 2013 to $844M in 2017. Direct cost NCI research grant support, excluding training grants and the CCSG, has increased 34%, from $67M in 2013 to $90M in 2018, with the largest number of NCI grants for any institution (>200), including 6 SPOREs, 4 P01s and 35 U awards. Research Programs have been reduced to 16 and support is requested for 14 shared resources. Since the last CCSG renewal, research has been strengthened with recruitment of 97 tenured and tenure track faculty, of whom 18 are supported by recruitment awards from CPRIT totaling $63M. Team science has been enhanced through institutional support of the MD Anderson's Moon Shots ($383M), focused on reducing mortality from 13 major cancers through multi-disciplinary efforts that build on research emerging from the CCSG programs. In FY17, 10,283 participants were enrolled in 1,108 interventional clinical research protocols, of which 936 were treatment (therapeutic) studies that accrued 6,271 subjects. Over the past decade MD Anderson investigators have contributed to the clinical evaluation of 72 of 130 FDA oncology drug approvals, either as a new entity or for a new indication, with 41 of these approvals since the last CCSG renewal. In addition to the main hospital, Houston Area Locations provide prospective, multidisciplinary care and supportive services, with an increasing emphasis on access to clinical trials including national studies. Cancer prevention and survivorship is a priority for MD Anderson with an emphasis on molecular epidemiology, behavioral science, clinical cancer prevention and early detection research to reduce the burden of cancer within Texas and worldwide.

项目摘要/摘要 MD安德森癌症中心是德克萨斯大学建立的综合癌症中心 系统于1941年。2017年，该机构欢迎医学博士彼得·皮斯特斯（Peter Pisters），成为其第五任全职总裁兼PI CCSG。 MD Anderson的使命是通过德克萨斯州，国家和世界消除癌症 纳入患者护理，研究和预防以及通过教育的杰出计划 本科生和研究生，学员，专业人士，员工和公众。 MD Anderson是 全面致力于研究涉及基本，临床和人群的连续体的癌症 调查，重点是多学科翻译研究。 MD Anderson雇用超过 2017财年的19,530人，其中包括1,743名教职员工，其中705名（40％）是CCSG计划成员。 在2017财年，有超过137,000人在MD安德森（MD Anderson）寻求护理，其中20,839人被新诊断出癌症 患者。从2013年的3,260人开始，网络科学的年度引文增长了23％，达到2017年的4,009个，包括 686（17％）在具有影响因子的期刊的期刊中的文章，在具有影响因子的期刊中的244（6％）文章 > 20。研究总预算从2013年的6.71亿美元增加到2017年的8.44亿美元。直接成本NCI研究 赠款支持（不包括培训补助金和CCSG）已从2013年的6700万美元增加到2018年的9000万美元， 任何机构的NCI赠款数量最多（> 200），其中包括6个孢子，4个P01和35个U奖项。 研究计划已减少到16，并要求提供14个共享资源的支持。自上次 CCSG更新，研究通过招募97名任期和任期教师的研究得到了加强 由CPRIT的招聘奖给予了6300万美元的招聘奖。团队科学已得到增强 通过机构支持MD Anderson的月球镜头（3.83亿美元），重点是减少13岁的死亡率 主要的癌症通过多学科的努力，基于CCSG计划的研究。在 2017财年，有10,283名参与者参加了1,108个介入临床研究方案，其中936个是 治疗（治疗）研究，该研究累积了6,271名受试者。在过去的十年中，MD Anderson调查人员 已作为新实体或 为了新的指示，自上次CCSG续签以来，有41个批准。除了主要医院， 休斯顿地区的地点提供潜在的，多学科的护理和支持服务，并且越来越多 重点是获得包括国家研究在内的临床试验。预防癌症和生存是优先事项 对于MD Anderson，重点是分子流行病学，行为科学，预防临床癌症 以及早期的检测研究，以减轻德克萨斯州和全球范围内的癌症负担。